Study background

The Murdoch Children’s Research Institute, University of Melbourne, Monash University and The Northern Hospital are conducting a study testing intranasal heparin to treat early COVID-19 infection.

Heparin is a naturally occurring sugar molecule which has been used for over 80 years to treat a range of medical problems. Recent studies suggest it binds the COVID-19 virus and may reduce the virus’ ability to enter cells.

We believe heparin may be able to treat people with early COVID-19 infections and prevent infection amongst their close household contacts, helping to reduce the spread of the virus.

Who can be in this study?

  • Any person aged over 5 years of age who tests positive to COVID-19 or is a household contact of someone of any age who tests positive to COVID-19.
  • At least one other person in each household must consent to participate to be randomized.​

Who is NOT eligible to be in this study?

  • Children aged less than 5 years cannot be randomized to therapy but can contribute to outcomes.
  • People with an allergy to heparin.
  • People with heparin-induced thrombocytopenia (HIT).
  • People with recurrent blood nose that has required hospitalization in the last 3 months.

Further information

Study flyer: INHERIT Study Flyer

Study contact email:

Site Principal Investigator (PI): Professor Donald Campbell

Chief Investigator (CI): Professor Paul Monagle